13D Filing: OrbiMed Advisors and Pieris Pharmaceuticals Inc. (PIRS)

Page 3 of 9 – SEC Filing

CUSIP No. 720795103
1
NAME OF REPORTING PERSONS
OrbiMed Capital GP III LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
5,500,730*
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
5,500,730*
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,500,730*
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.78%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
____________________
*  This percentage is calculated based upon 51,029,849  shares of common stock, par value $0.001 per share (the “Shares”), outstanding of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Issuer”), as set forth in the Issuer’s Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 20, 2018.

Follow Pieris Pharmaceuticals Inc. (NYSE:PIRS)